SCHEMBL24826487

SCHEMBL24826487

CS(=O)(=O)O[C@H]1CN(C(c2ccccc2)c2ccccc2)[C@@H]1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.36
CYP3A4 P08684 4/20 0.36
OPRD1 P41143 5/20 0.36
OPRM1 P35372 4/20 0.36
OPRK1 P41145 4/20 0.36
OPRL1 P41146 4/20 0.36
ALOX15 P16050 1/20 0.35
TSHR P16473 3/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
PMP22 Q01453 1/20 0.34
KMT2A Q03164 1/20 0.34
SLC6A2 P23975 1/20 0.34
CYP2C19 P33261 2/20 0.33
USP2 O75604 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5450723 0.84 OPRD1 (0.38) CYP2D6CYP3A4OPRD1OPRM1OPRK1
SCHEMBL5458868 0.84 OPRD1 (0.38) CYP2D6CYP3A4OPRD1OPRM1OPRK1
SCHEMBL30642715 0.84 OPRD1 (0.38) CYP2D6CYP3A4OPRD1OPRM1OPRK1
SCHEMBL5458873 0.84 OPRD1 (0.38) CYP2D6CYP3A4OPRD1OPRM1OPRK1
SCHEMBL2849250 0.81 OPRD1 (0.36) CYP2D6CYP3A4OPRD1ALOX15TSHR
SCHEMBL2849251 0.81 OPRD1 (0.36) CYP2D6CYP3A4OPRD1ALOX15TSHR
SCHEMBL2850422 0.81 OPRD1 (0.36) CYP2D6CYP3A4OPRD1ALOX15TSHR
SCHEMBL5744342 0.79 CYP2D6 (0.39) CYP2D6CYP3A4OPRD1OPRM1OPRK1
SCHEMBL5744958 0.74 CYP2D6 (0.42) CYP2D6CYP3A4OPRD1OPRM1OPRL1
SCHEMBL27262604 0.74 DPP4 (0.38) CYP2D6CYP3A4OPRD1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022271612-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION (US) 2022-12-29 WO disclosed